Mouse Hybridoma based Antibody Discovery Service

Introduction Antigen Preparation Immunizations Hybridoma Development Antibody Synthesis Features

Creative Biolabs offers services for the construction of rat and mouse monoclonal antibodies. Notably, our exclusive approach to mouse immunization enables the production of mouse monoclonal antibodies within a timeframe of 70 days.

One-Stop Murine Hybridoma Services

To produce monoclonal antibodies tailored to your precise needs, we customize our protocols at each pivotal stage of antibody synthesis. This encompasses the preparation of antigens (involving the synthesis of peptides or the expression of proteins in diverse platforms such as E. coli, yeast, insects, or mammalian cells), animal immunization, and the screening of hybridomas.

Fig. 1 The workflow of murine hybridoma. (Creative Biolabs Original)

Antigen Preparation

We proficiently express and refine your recombinant proteins utilizing suitable expression systems in E. coli, yeast, insects, or mammalian cells, aligning with the specific objectives of the ensuing antibodies.
Our exclusive technique for chimeric protein expression enables the generation of a soluble form of recombinant protein immunogens within bacterial cells, preserving the original protein's specificity and immunogenicity. This method enhances the likelihood of obtaining monoclonal antibodies yielding positive results in IHC assays, as well as antibodies capable of recognizing the native protein, suitable for employment in ELISA, IP, IF, and Western blotting.
We can devise membrane mimic protein antigens (MMPAs) that maintain structural characteristics akin to multi-span extracellular domains.
Alternatively, we execute peptide synthesis and conjugation methodologies.

Immunizations

We employ tailored protocols for animal immunizations, encompassing appropriate adjuvants, inoculation routes, dosages, and timing.
Our exclusive adjuvant induces a heightened and accelerated immune response in just 21 days.
Our expedited mouse immunization protocol enables the provision of monoclonal antibodies within 70 days.

Development of Hybridoma

Utilizing refined PEG-mediated fusion methodologies, we merge splenocytes with compatible myeloma cells.
Hybridoma clone screening entails bespoke protocols tailored to the intended applications of the requested antibodies, encompassing techniques such as immunoprecipitation, immunoblotting, various ELISA formats, and notably, IHC.
Utilizing a precise methodology to pinpoint monoclonal antibodies suitable for immunohistochemistry (IHC), we introduce our IHC-positive hybridoma screening services.
Our groundbreaking Omni-Hybridoma™ platform enables the efficient selection of numerous hybridoma clones post-fusion, mitigating the risk of fast-growing clones outcompeting potentially valuable slow-growing counterparts.
We deliver positive hybridoma clones either in culture or cryopreserved, along with the corresponding monoclonal antibodies derived from them.

Ascites Generation or In Vitro Antibody Synthesis

Introduction of hybridoma cells into suitable animal hosts to induce ascites production. Typically, we employ immunocompetent mice for ascites generation. Nevertheless, immuno-compromised mice are accessible for non-murine hybridoma cell lines or murine cell lines exhibiting distinct genetic backgrounds. Refined methodologies are employed to initiate tumor formation and accumulate ascitic fluid. The utilization of nude or severe combined immunodeficient (SCID) mice in ascites production serves to eliminate potential contamination from endogenous mouse IgG.
Cultivation of cells in protein-free culture medium. Monoclonal antibody manufacturing is facilitated using stationary flasks or bioreactors ranging from 5-50 liters in capacity. Our antibody fermentation capabilities exceed 300 liters.

Features of Murine Hybridoma Services in Creative Biolabs

Exceptional specificity and affinity in the picomolar range;
Capacity to produce extensive arrays of functional antibodies;
Capability to discern subtle alterations including post-translational modifications;
Identification of novel epitopes;
Outstanding outcomes even for challenging antigens;
Availability of assays including ELISA, FACS, ICC, IHC, WB, and flow cytometry;

Creative Biolabs boasts a wealth of expertise garnered from numerous case studies in hybridoma technology services, and we cordially invite you to engage in discussions regarding any challenges or solutions pertinent to your project. Please do not hesitate to reach out to us at your convenience.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: